Thrombolytic Therapy and Modern Vascular Surgery: An Overview

Kwaan HC Hematologic aspects of thrombolytic therapy. In Comerota AJ , ed. Thrombolytic Therapy. Orlando, Fla.: Grune & Stratton, 1988, pp 17-28.

Christensen LR Streptococcal fibrinolysis: A proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysis. J Gen Physiol 28:363, 1945.

Alkjaersig N. , Fletcher AP , Sherry S. The mechanism of clot dissolution by plasmin . J Clin Invest 38:1086, 1959.

Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 48:177, 1980.

Sherry S. , Fletcher AP , Alkjaersig N. The mechanism of clot dissolution by plasmin. Ann Intern Med 50:560, 1959.

Robbins KC The human plasma fibrinolytic system; Regulation and control. Mol Cell Biochem 20:149, 1978.

Robbins KC , Summaria L. Plasminogen and plasmin. In Lorand L , ed. Methods in Enzymology. New York : Academic Press, 1976, p 257.

DeRenzo EC , Siiteri PK , Hutchings BL , et al. Preparations and certain properties of highly purified streptokinase . J Biol Chem 137:533, 1967.

Jackson KW , Tang J. Complete amino acid sequence of streptokinase and its homology with serine proteases. Biochemistry 21:6620, 1982.

Barlow GH , Summaria L. , Robbins KC Hydrodynamic studies on the streptokinase complexes of human plasminogen, Val442-plasminogen, plasmin and the plasmin derived light (B) chain. Biochemistry 23:1284, 1987.

Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 43:77, 1989.

Cassels R. , Fears R. , Smith RAG. The interaction of streptokinase plasminogen activator complex, tissue type plasminogen activator, urokinase and their acylated derivations with fibrin and cyanogen bromide digests of fibrinogen. Biochem J 247:395, 1987.

Siegfring GE , Castellino FJ Interaction of streptokinase with plasminogen. Isolation and characterization of SK degradation products. J Biol Chem 251:3913, 1976.

Verstraete M. , Collen D. Pharmacology of thrombolytic drugs . J Am Coll Cardiol 8:33-B, 1986.

Fletcher AP , Alkjaersig N. , Sherry S. The clearance of heterologous protein from the circulation of normal and immunized man. J Clin Invest 37:1306, 1959.

Robbins KC , Barlow GH , Nguyen G. , et al. Comparison of plasminogen activators. Semin Thromb Hemost 13:131, 1987.

Verstraete M. , Vermylen J. , Amery A. , et al. Thrombolytic therapy with streptokinase using a standard dosage scheme. Br Med J 1:454, 1966.

Mentzer RL , Brudzinski AZ , Sherry S. High dose brief duration intravenous infusion of streptokinase in acute myocardial infarction: Description of effects in circulation. Am J Cardiol 57:1220, 1986.

Fears R. Development of anisoylated plasminogen-streptokinase activator complex from the acyl enzyme concept. Semin Thromb Hemost 15(2):129, 1989.

Smith RAG , Dupe RJ , English PD , et al. Fibrinolysis with acyl enzymes: A new approach to thrombolytic therapy. Nature 290:505, 1981.

Ernshaw JJ , Westby JC , Makin GS , et al. The systemic fibrinolytic effect of BRL 26921 during treatment of acute peripheral occlusion. Thromb Haemost 55:259, 1986.

Marder VJ , Francis CW , Norry EC Dose ranging study of acylated streptokinase-plasminogen complex BRL 26921 . Thromb Haemost 50:321, 1983.

Pennel R. , Gurewich V Pro-urokinase—A study of its stability in plasma and a mechanism for its selective fibrinolytic effect. Blood 67:1215, 1986.

Linjen HR , Zamarron C. , Bluber M. , et al. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 261:1253, 1986.

Collen D. , Zamarron C. , Linjen HR , et al. Activation of plasminogen by urokinase. II. Kinetics. J Biol Chem 261:1259, 1986.

Collen D. , Stassen JM , Bluber M. , et al. Biological and thrombolytic properties of pro-enzyme and active forms of human urokinase. III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemost 52:27, 1984.

Holmes WE , Pennica D. , Bluber M. , et al. Cloning and expression of the gene for urokinase in Escherichia coli. Biotechnology 3:923, 1985.

Gurewich V. , Pennell R. , Lowe S. , et al. Effective and fibrin specific clot lysis by a zymogen precursor form of urokinase (pro-UK). A study in vitro and in two animal species. J Clin Invest 73:1731, 1984.

Collen D. , Stump D. , Van de Werf F. , et al. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase. Circulation 72:384, 1985.

Marder VJ , Sherry S. Thrombolytic therapy; Current status. N Engl J Med 318:1512, 1988.

White WF , Barlow GH , Mozen MN The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5:2160, 1966.

Samama M. , Szwarcer E. , Nguyen G. , et al. Comparison of fibrinolytic, thrombolytic, and fibrinogenolytic activities of high and low molecular weight urokinase (HMW- and LMW-UK) and tissue plasminogen activator in vitro. Thromb Haemost 54:43, 1985.

Van Hinsberg VWM , Sprengers ED , Kooistra T. Effect of thrombin on the production of plasminogen activators and PA-1 inhibitors by human foreskin microvascular cells. Thromb Haemost 57:148, 1987.

Rijken DC , Hoylaerts M. , Collen D. Fibrinolytic properties of one and two chain human extrinsic (tissue type) plasminogen activator. J Biol Chem 257:2920, 1982 .

Korninger C. , Collen D. Neutralization of human extrinsic (tissue type) plasminogen activator in human plasma. No evidence for a specific inhibitor . Thromb Haemost 46:662, 1981.

Rao AK , Pratt C. , Berke A. , et al. Thrombolysis in myocardial infarction (TIMI) trial— Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:141, 1988.

Gurewich V. , Pennel R. Clot lysis by pro-urokinase and t—PA—A comparative study. Thromb Haemost 54:122, 1985.

Gurewich V. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase. Semin Thromb Hemost 15:123, 1989.

Nieuwenhuizen W. , Vermond A. , Voskuilen M. , et al. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue type plasminogen activator. Biochim Biophys Acta 86:748, 1983.

Collen D. , Stassen JM , Stump DC , et al. In vivo synergism of thrombolytic agents. Circulation 74:838, 1986.

Collen D. , Van de Werf F. Coronary arterial thrombolysis with low dose synergistic combinations of recombinant tissue type plasminogen activator for acute myocardial infarction . Am J Cardiol 60:431, 1987.

Barlow GH Urinary and kidney cell plasminogen activator (urokinase). Methods Enzymol 45:239, 1976.

Van de Werf F. , Vanhaecke J. , de Geest H. , et al. Coronary thrombolysis with recombinant single chain urokinase type plasminogen activator in patients with acute myocardial infarction. Circulation 74:1066, 1986.

Garabedian HD , Gold HK , Leinbach RC , et al. Comparative properties of two clinical preparations of recombinant human t-PA in patients with acute myocardial infarction . J Am Coll Cardiol 9:599, 1987.

Fletcher AP , Alkjaersig N. , Sherry S. , et al. The development of urokinase as a thrombolytic agent; Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 65:71, 1965.

Fennerty AG , Levine MN , Hirsch J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism . Chest 95:885-S, 1989.

Mueller HS , Koneti J. , Rao AE , et al. Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue type plasminogen activator. J Am Coll Cardiol 10:479, 1987.

Rao AE , Pratt C. , Berke A. Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue type plasminogen activator and streptokinase. J Am Coll Cardiol 11:1, 1988.

Towne JB , Bandyk DE Application of thrombolytic therapy in vascular occlusive disease: A surgical view. Am J Surg 154:548, 1987.

American Heart Association. Heart facts. Dallas: American Heart Association, 1986.

Kennedy JW Streptokinase for the treatment of acute myocardial infarction: A brief review of randomized trials. J Am Coll Cardiol 10:28-B, 1987.

Herrick JB Clinical features of sudden obstruction of the coronary arteries. JAMA 59: 2015, 1912.

Fletcher AP , Sherry S. , Alkjaersig N. , et al. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 38:1111, 1959.

Boucek HJ , Murphy WP Segmental perfusion of the coronary arteries with fibrinolysis in man following a myocardial infarction. Am J Cardiol 5:525, 1960.

Ehrlich JC , Shinohara Y. Low incidence of coronary thrombosis in myocardial infarction: A re-study by serial block technique. Arch Pathol 78:432, 1964.

Sobel BE , Bresnaham GF , Shell WE , et al. Estimation of infarct size in man and its relation to prognosis . Circulation 46:640, 1972.

De Wood MA , Spores J. , Notske R. , et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction . N Engl J Med 303:897, 1980.

Rude RE , Muller JE , Braunwald E. Efforts to limit the size of myocardial infarcts. Ann Intern Med 95:736, 1981.

Van de Werf F. , Nobuhara M. , Collen D. Coronary thrombolysis with human single chain urokinase type plasminogen activator in patients with acute myocardial infarction . Ann Intern Med 104:345, 1986.

Van de Werf F. , Vanhaecke J. , DeGeest H. , et al. Coronary thrombolysis with recombinant single chain urokinase type plasminogen activator in patients with acute myocardial infarction. Circulation 74:1066, 1986.

AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo controlled clinical trial. Lancet 1:545, 1989.

Ikram S. , Lewis S. , Bucknell C. , et al. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Br Med J 293:786, 1986.

Rappaport E. Thrombolytic agents in acute myocardial infarction . N Engl J Med 320:861, 1989.

Rentrop KP , Felt F. , Blanke H. , et al. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N Engl J Med 311:1457, 1984 .

Verstraete M. , Arnold AER , Brower RW , et al. Acute coronary thrombolysis with recombinant human tissue type plasminogen activator: Initial patency and influence of maintained infusion on re-occlusion rate . Am J Cardiol 60:231, 1987.

Sheehan FH , Braunwald E. , Canner P. , et al. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue type plasminogen activator and streptokinase from the thrombolysis in myocardial infarction (TIMI) phase I trial. Circulation 75:817, 1987.

Kennedy JW , Ritchie JL , Davis KB , et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 309:1477, 1983.

Kennedy JW , Ritchie JL , Davis KB , et al. The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction: A 12-month follow-up report. N Engl J Med 312:1073, 1985.

Gruppo Italiano per lo studio della Streptochinasi Nell' Infarcto Miocardio (GISSI); Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction . Lancet 1:397, 1986.

Topol EJ , Califf RM , George BS , et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction . N Engl J Med 317:581, 1987.

Passamani E. , Hodges M. , Herman M. , et al. The thrombolysis in myocardial infarction (TIMI) phase II pilot study: Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 10:51-B, 1987.

Simoons ML , Arnold AER , Betriu A. , et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous transluminal angioplasty. Lancet 1:197, 1988.

The TIMI study group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the TIMI phase II trial. N Engl J Med 320:618, 1989.

ISIS pilot study investigation. Randomized factorial trial of high dose intravenous streptokinase, of oral aspirin, and of intravenous heparin in acute myocardial. Eur Heart J 8:634, 1987.

ISIS 2 collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1:2134, 1988.

Antiplatelet trialists collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment . Br Med J 296:320, 1988.

Barritt DW , Jordan SC Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial . Lancet 1:1309, 1960.

Arneson H. , Heilo A. , Jokobsen E. , et al. A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 203:457, 1978.

Elliot MS , Immelman EJ , Jeffrey P. , et al. A comparative randomized trial of heparin vs. streptokinase in the treatment of acute proximal venous thrombosis; An interim report of a prospective trial. Br J Surg 66:838, 1979.

Kakkar VV , Flane C. , Howe CT , et al. Treatment of deep vein thrombosis. A trial of heparin, streptokinase and Arvin. Br Med J 1:806, 1969.

Marder VJ , Soulen RL , Atichartakarn V. , et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 89:1018, 1977.

Robertson BR , Nilsson IM , Nylander G. Value of streptokinase and heparin in treatment of acute deep vein thrombosis. Acta Chir Scand 134:203, 1968.

Robertson BR , Nilsson IM , Nylander G. Thrombolytic effect of streptokinase as evaluated by phlebography of deep vein thrombosis of the leg. Acta Chir Scand 136:173, 1970.

Seaman AJ , Common HH , Rosch J. , et al. Deep vein thrombosis treated with streptokinase or heparin. A randomized study. Angiology 27:549, 1976.

Tsapogas MJ , Peabody RA , Wu KT , et al. Controlled study of thrombolytic therapy in deep vein thrombosis. Surgery 74:973, 1973.

Pilla T. , Comerota AJ Basic data related to thrombolytic therapy for venous thrombosis. Ann Vasc Surg 3:81, 1989.

Arnesen H. , Hoiset A. , Ly B. , et al. Streptokinase or heparin in the treatment of deep vein thrombosis—Follow-up results of a prospective study. Acta Med Scand 211:65, 1982.

Common HH , Seaman AR , Rosch J. , et al. Deep vein thrombosis treated with streptokinase or heparin; Follow-up of a randomized study. Angiology 27:645, 1976.

Johanson L. , Nylander G. , Hedner U. , et al. Comparison of streptokinase with heparin: Late results in the treatment of deep vein thrombosis . Acta Med Scand 206:93, 1979.

Kakkar VV , Lawrence D. Hemodynamic and clinical assessment of the etiology for acute deep vein thrombosis . A prospective study Am J Surg 10:54, 1985.

Van de Loo JCW , Kriessman A. , Trubstein G. , et al. Controlled multicenter pilot study of urokinase, heparin and streptokinase in deep vein thrombosis . Thromb Haemost 50:660, 1983.

Samama MM Deep vein thrombosis of inferior limbs; Are thrombolytic agents superior to heparin. Semin Thromb Hemost 13:178, 1987.

Urokinase pulmonary embolism trial—Phase I results. JAMA 214:2163, 1974.

Urokinase-streptokinase pulmonary embolism trial—Phase II results. JAMA 229:1606, 1974.

Upet investigators . Urokinase in pulmonary embolism trial. Circulation 47&48 (Suppl II):1, 1973.

Ward BJ , Pearse DB Reperfusion pulmonary edema after thrombolytic therapy of massive pulmonary embolism. Ann Rev Respir Dis 138:1308, 1988 .

Martin TR , Sandblom RL , Johnson RJ Adult respiratory distress syndrome following thrombolytic therapy for pulmonary embolism. Chest 83:151, 1983.

Goldhaber SZ , Vaughan DE , Markis JE , et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 2:886, 1986.

Ceme PC , Kim D. , Parker JA , et al. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with tissue plasminogen activator . J Am Coll Cardiol 10:971, 1987.

Verstraete M. , Miller GAH , Bounameaux H. , et al. Intravenous and intrapulmonary recombinant tissue type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 77:353, 1988.

Goldhaber SZ , Kessler CM , Heit J. , et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1:293, 1988.

Sharma GV , Burleson VA , Sassahara AA Effect of thrombolytic therapy on pulmonary capillary blood volume in patients with pulmonary embolism. N Engl J Med 303:842, 1980.

Del Campo C. Massive pulmonary embolism; A review. Can J Surg 161:481, 1985.

Rosenthal D. , Evans RD , Borrero E. , et al. Massive pulmonary embolism: Triple-armed therapy. J Vasc Surg 9:261, 1989.

Martin M. Thrombolytic therapy in arterial thromboembolism. Prog Cardiovasc Dis 21: 351, 1979.

Martin M. , Schoop W. , Zeittler E. Streptokinase in chronic arterial occlusive disease. JAMA 211:1169, 1970.

Poliwoda H. , Alexander K. , Buhl J. , et al. Treatment of chronic arterial occlusions with streptokinase. N Engl J Med 280:689, 1969.

Chesterman CN , Nash T. , Biggs JL Small vessel thrombosis following vascular injury. Successful treatment with a low dose intra-arterial infusion of streptokinase . Br J Surg 58: 882, 1971.

Dotter CT , Rosch J. , Seaman AJ Selective clot lysis with low dose streptokinase. Radiology 111:31, 1974.

Katzen RT , Edwards KC , Albert AS , et al. Low dose direct fibrinolysis in peripheral vascular disease . J Vasc Surg 1:718, 1984.

Lammer J. , Pilger E. , Neumayer K. , et al. Intra-arterial fibrinolysis: Long term results. Radiology 161:159, 1986.

Hess H. , Mietaschk A. , Bruckl R. Peripheral arterial occlusions: A 6-year experience with local low dose thrombolytic therapy. Radiology 163:753, 1987.

Belkin M. , Donaldson MC , Whittemore AD , et al. Vein graft patency after successful thrombolysis and revision . J Vasc Surg Feb 1990 (in press).

Van Breda A. , Katzen BT , Deutsch AS Urokinase vs. streptokinase in local thrombolysis . Radiology 165:109, 1987.

Parent FH , Bernhard VM , Pabst TS , et al. Fibrinolytic treatment of residual thrombus after catheter embolectomy for severe lower limb ischemia. J Vasc Surg 9:153, 1989.

Graor RA , Risius B. , Young JR Peripheral artery and bypass graft thrombolysis with recombinant human tissue type plasminogen activator. J Vasc Surg 3:115, 1986.

Hess H. , Ingrisch A. , Mietaschk A. , et al. Local low dose thrombolytic therapy of peripheral arterial occlusions . N Engl J Med 307:627, 1982.

Hume M. , Gurewich V. , Thomas DP , et al. Streptokinase for chronic arterial occlusive disease. Arch Surg 101:653, 1970.

Hallett JW , Greenwood LH , Yrizzary JM , et al. Statistical determinants of success and complications of thrombolytic therapy for arterial occlusions of the lower extremity. Surg Gynecol Obstet 161:431, 1985.

Berni GA , Bandyk DF , Zierler RE , et al. Streptokinase treatment of acute arterial occlusion. Ann Surg 198:185, 1982.

Comerota AJ , Rubin RN , Tyson RR , et al. Intra-arterial thrombolytic therapy in peripheral vascular disease. Surg Gynecol Obstet 165:1, 1987.

Towne JB , Bandyk DF Application of thrombolytic therapy in vascular occlusive disease . Am J Surg 154:548, 1987.

Quiñones-Baldrich WJ , Deutsch LS Fibrinolytic therapy for acute arterial occlusions . Vasc Reports 2:6, 1986.

Graor RA , Risius B. , Young JR , et al. Thrombolysis of peripheral arterial bypass grafts: Surgical thrombectomy compared with thrombolysis. J Vasc Surg 7:347, 1988.

Perler BA , White RI , Ernst CB , et al. Low dose thrombolytic therapy for infrainguinal graft occlusions; An idea whose time has passed? J Vasc Surg 2:799, 1985.

Cohen H. , Kaplan M. , Bernhard VM Intraoperative streptokinase—An adjunct to mechanical thrombectomy in the management of acute ischemia. Arch Surg 121:708, 1986.

Quiñones-Baldrich WJ , Baker JD , Bussutil RW , et al. Intraoperative infusion of lytic drugs for thrombotic complications of revascularization . J Vasc Surg 7:347, 1988.

Ricota JJ , Green RM , DeWeese JA Use and limitations of thrombolytic therapy in the treatment of peripheral arterial ischemia: Results of a multi-institutional questionnaire. J Vasc Surg 6:645, 1987.

Dacey LJ , Dow RW , McDaniel MD , et al. Cost effectiveness of intra-arterial thrombolytic therapy. Arch Surg 123:1218, 1988.

Taylor LM Jr , Porter JM , Baur GM , et al. Intra-arterial streptokinase infusion for acute popliteal and tibial artery occlusion. Am J Surg 147:583, 1984.